Institutional Chairs

5

5

Vildagliptin is an oral DPP-4 inhibitor approved for the treatment of type 2A diabetes. By inhibiting DPP-4 and increasing GLP-1 levels, it results in higher insulin levels and lower glucose levels, particularly after eating.

Vildagliptin is an oral DPP-4 inhibitor approved for the treatment of type 2A diabetes. By inhibiting DPP-4 and increasing GLP-1 levels, it results in higher insulin levels and lower glucose levels, particularly after eating.

50mg

50mg

When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening.

When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening.

10X10's Aluminium foil

10X10's Aluminium foil

Yes

Yes

All India

All India